Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial February 16, 2023May 23, 2023
Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office December 29, 2022May 23, 2023
